Figures & data
Table 1 Characteristics of Patients and the Visits in the Cohort
Figure 1 Trends in the proportion of patients filling at least one prescription (A) and average dose-adjusted number of canisters (B) for major COPD inhaled therapies, during disease course.
![Figure 1 Trends in the proportion of patients filling at least one prescription (A) and average dose-adjusted number of canisters (B) for major COPD inhaled therapies, during disease course.](/cms/asset/1f327ce5-0797-4e65-83d8-8b211eed147c/dcop_a_12163777_f0001_c.jpg)
Figure 2 Trends in the proportion of patients on combination therapies (A) and average medication possession ratio (B) over the time course of COPD.
![Figure 2 Trends in the proportion of patients on combination therapies (A) and average medication possession ratio (B) over the time course of COPD.](/cms/asset/c5aa582a-ceef-4397-a39b-86a725897cfd/dcop_a_12163777_f0002_c.jpg)
Figure 3 Frequency of long-acting inhaled medication prescription in frequent (dark bars) and non-frequent (light bars) exacerbators.
![Figure 3 Frequency of long-acting inhaled medication prescription in frequent (dark bars) and non-frequent (light bars) exacerbators.](/cms/asset/1ee3f57d-10ca-478e-aa2f-53ff731bc12c/dcop_a_12163777_f0003_b.jpg)
Figure 4 Forest plot of odds ratio (OR) and 95% confidence interval between frequent-exacerbator status and filled prescriptions for each medication type, separately for GP and specialist compared to non-frequent exacerbators.
![Figure 4 Forest plot of odds ratio (OR) and 95% confidence interval between frequent-exacerbator status and filled prescriptions for each medication type, separately for GP and specialist compared to non-frequent exacerbators.](/cms/asset/3364d13b-f363-4bab-af89-27b0493b1fbf/dcop_a_12163777_f0004_b.jpg)